The present invention relates to a method for assessing myocardial infarction comprising the steps of determining the amount of a first biomarker in a sample of a subject, said first biomarker being a cardiac Troponin, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: a BMP 10-type peptide (Bone Morphogenic Protein 10-type peptide), FGF23 (Fibroblast growth factor 23), a BNP -type peptide, cardiac myosin binding protein C (cMyBPC) and ANG2 (Angiopoietin 2), comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing myocardial infarction based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being a cardiac Troponin and a second biomarker selected from the group consisting of: a BMP 10-type peptide (Bone Morphogenic Protein 10-type peptide), FGF23 (Fibroblast growth factor 23), a BNP -type peptide, cardiac myosin binding protein C (cMyBPC) and ANG2 (Angiopoietin 2), or at least one detection agent for said first biomarker and at least one detection agent for said second biomarker for assessing myocardial infarction. Moreover, the invention further relates to a computer-implemented method for assessing myocardial infarction and a device and a kit for assessing myocardial infarction.
The present invention relates to a method for assessing myocardial infarction comprising the steps of determining the amount of a first biomarker in a sample of a subject, said first biomarker being cMyBPC, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: a BMP10- type peptide (Bone Morphogenic Protein 10-type peptide), FGF23 (Fibroblast growth factor 23), a BNP-type peptide (Brain natriuretic peptide type peptide), GDF-15 (Growth differentiation factor 15), ANG2 (Angiopoietin 2), CRP (C-reactive protein), ESM1 (endothelial cell specific molecule 1), or a lipid biomarker, such as Cholesterol, LDL (Low Density Lipoprotein) or APOAT (Apolipoprotein A-1) comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing myocardial infarction based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being cMyBPC and a second biomarker selected from the group consisting of: a BMP10-type peptide, FGF23, a BNP-type peptide, GDF15, ANG2, CRP (C-reactive protein), ESM1, or a lipid biomarker, such as Cholesterol or LDL, or at least one detection agent for said first biomarker and at least one detection agent for said second biomarker for assessing myocardial infarction. Moreover, the invention further relates to a computer-implemented method for assessing myocardial infarction and a device and a kit for assessing myocardial infarction.
The present invention includes: a reagent vessel holding part that holds a reagent vessel for accommodating a reagent; a reagent vessel information detection unit that detects information relating to the reagent vessel; a display unit that displays a screen including an operation region where operations from a user are received; and a control unit that causes the display unit to display the screen. The control unit has: a vessel presence/absence determination unit that determines whether the reagent vessel is present in the reagent vessel holding unit on the basis of the information detected by the reagent vessel information detection unit; a first operation region output unit that outputs, to the screen, a first operation region which is operated when the user has confirmed removal of the reagent vessel; a second operation region output unit that outputs, to the screen, a second operation region which is operated when shutdown is performed; and a warning output unit that outputs, to the screen, a warning prompting removal of the reagent vessel when the vessel presence/absence determination unit has determined that the reagent vessel is present. The foregoing makes it possible to provide an automated analysis device which prevents shutdown from starting while a reagent has been left behind.
The present invention relates to a method for determining at least one analyte of interest and the use thereof. The present invention further relates to a kit, a complex, a method to synthesize a complex, a monomer and the use thereof for detecting the analyte of interest in the sample.
The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being DLL1, determining the amount of a second biomarker in a sample of the subject, said second biomarker being GDF15, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being DLL1 and a second biomarker being GDF15, or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
A method of cross-flow filtering wastewater from a diagnostic apparatus or a laboratory analyser, wherein the wastewater comprises nanoparticles and/or microparticles, and the wastewater is streaming in a laminar flow across a surface of a filter membrane, the method comprising: (a) streaming the wastewater across the surface of the filter membrane with a flow rate, so that the flow of the wastewater is a laminar flow with a Reynolds number (Re) of smaller than 500; (b) streaming the wastewater in pulse cycles across the surface of the filter membrane, wherein each pulse cycle comprises one active phase in which the wastewater is under a duty pressure and one inactive phase in which the wastewater is under an inactive pressure, wherein the inactive pressure is no more than 10% of the duty pressure and the active phases have a duration of greater than 50 % of the corresponding pulse cycles; and (c) separating the nanoparticles and/or microparticles from the wastewater when the wastewater passes through the filter membrane. Also described is a cross-flow filtration system configured for performing the method.
Provided is a component abnormality detecting system for detecting an abnormality of a component of a liquid transport system that sucks in and discharges a liquid to and from a sample inspection sensor of an automated analyzing device, the component abnormality detecting system comprising a storage device for storing data of an electrical signal output by the sensor, and a processing device for processing the data recorded in the storage device, wherein the processing device detects an abnormality of a component of the liquid transport system on the basis of the electrical signal.
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor
G01N 35/08 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a stream of discrete samples flowing along a tube system, e.g. flow injection analysis
pRR0000p0000p0iiiii, a statistical parameter derived from a linear regression of the plurality of past eGFR values; and applying a machine-learning model to the input data to generate an output indicating the likelihood of kidney failure within the given amount of time Δt. Corresponding training methods and systems are also provided.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
9.
METHOD FOR OPERATING LABORATORY SYSTEM AND LABORATORY SYSTEM
A method for operating a laboratory system is disclosed, comprising providing a laboratory system having a plurality of sample containers (1) configured to contain a sample to be processed for at least one of pre-analysis and analysis in the laboratory system; a plurality of laboratory devices (2; 3; 4; 6) providing for a plurality of target devices each configured to handle one or more sample containers from the plurality of sample containers (1), the one or more sample containers being assigned for handling to the target device in operation of the laboratory system; and a control device (5) configured to at least control assignment of the plurality of sample containers (1) to the plurality of target devices; and assigning the plurality of sample containers (1) to the plurality of target devices in operation of the laboratory system. The assigning comprises: determining a target device workload state for each of the plurality of target devices, the target device workload state being in a range between a first range limit indicative of a first capacity for handling sample containers and a second range limit indicative a second capacity for handling sample containers, the second capacity being a higher capacity than the first capacity for handling sample containers, and determined according to a metric being proportional to a resource target device state indicative of a present number of sample containers assigned to the target device, and a power of an output flow of the target device, the output flow being indicative of output of sample containers per time by the target device; assigning the plurality of sample containers (1) to the plurality of target devices according to the target device workload states; and providing the plurality of sample containers (1) to the plurality of target devices for handling according to the assignment. Furthermore, a laboratory system is provided.
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor
G05B 19/042 - Programme control other than numerical control, i.e. in sequence controllers or logic controllers using digital processors
G05B 19/418 - Total factory control, i.e. centrally controlling a plurality of machines, e.g. direct or distributed numerical control (DNC), flexible manufacturing systems (FMS), integrated manufacturing systems (IMS), computer integrated manufacturing (CIM)
G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
10.
A COMPOSITION FOR DETERMINING AT LEAST ONE ANALYTE OF INTEREST VIA MASS SPECTROMETRY MEASUREMENTS
The present invention relates to a composition for determining at least one analyte of interest via Mass Spectrometry measurements and uses thereof, a kit and the use thereof, a method of determining the level of at least one analyte of interest in an obtained sample, a sampling tube for collecting a patient sample, an analyzer as well as the use of dialkyl sulfide as an additive in a formulation of β-lactam antibiotic analyte for preventing oxidation.
The present invention relates to a method of determining the level of at least one analyte of interest, sampling tubes for collecting a patient sample, the use of nucleophilic derivatization reagents, an analyzer as well as kits.
The invention relates to a laboratory apparatus (1), wherein the laboratory apparatus (1) comprises, - a housing (2), wherein the housing (2) comprises a through-opening (3), wherein the through-opening (3) is adapted for passing through it a transport device (4) for transporting laboratory sample containers (5) in and/or out of the housing (2), and - a cover (6), wherein the cover (6) comprises at least two ring segments (7a, 7b), wherein the ring segments (7a, 7b) are adjustable to each other between a distant adjustment (da) with at least one distance (Dla, Dlb) in between ends (7aE, 7bE) of the ring segments (7a, 7b) for arranging them around the passed through transport device (4) and a near adjustment (na) with less or no distance in between the ends (7aE, 7bE) of the ring segments (7a, 7b) for surrounding the passed through transport device (4), and wherein the cover (6) in the near adjustment (na) is adapted to cover a part (3f) of the through-opening (3) left free by the passed through transport device (4), - wherein the laboratory apparatus (1) is a pre-analytical, analytical, and/or post-analytical laboratory apparatus (1'), in particular a sorting module (1").
A computer-implemented method of differentiating between lymphoid blast cells and myeloid blast cells comprises: receiving (S30) a digital image containing one or more blast cells; applying (S34) a parametric model classifier (412) to one or more portions of the digital image each containing a respective blast cell, the parametric model (416) configured to generate an output (S38) indicative of whether each blast cell is a lymphoid blast cell or a myeloid blast cell. Computer- implemented methods of training a parametric model (416) are also provided, as well as a clinical decision support system (400) relying on the computer-implemented method of classifying blast cells.
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
14.
MODIFIED ANTIBODY FOR SITE-SPECIFIC CONJUGATION AND ITS DIAGNOSTIC USE
The present invention relates to a modified antibody comprising a heavy chain and a light chain, wherein the antibody is modified to include in one or more of its immunoglobulin polypeptide chains one or more first recognition site(s) for the transglutaminase from Kutzneria albida (KalbTG) or a functionally active variant thereof. The one or more first recognition site(s) are introduced at one or more selected position(s) within an antibody's heavy chain and/or an antibody's light chain. The invention further relates to one or more nucleic acid(s) encoding an immunoglobulin polypeptide chain including the one or more recognition site(s), a site-specifically conjugated antibody comprising the modified antibody and one or more labelling domain(s) covalently attached to one or more first recognition sites, a kit for producing the conjugated antibody, a method of specifically labelling the modified antibody by way of site-specific conjugation, the use of the modified antibody for producing a specifically site-specifically conjugated antibody, a method of detecting a target in a sample and the use of the site-specifically conjugated antibody in the detection of a target and/or in the diagnosis.
A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
A method of determining the concentration of at least one analyte in a sample (112) is proposed. The method comprises: i. providing at least one sensor device (110), the sensor device (110) comprising - at least one field effect transistor (114) having at least one source electrode (116), at least one drain electrode (118) and at least one gate electrode (120), • - at least one sensing electrode (132) configured for being in contact with the sample (112), the sensing electrode (132) being at least one of electrically connected to the gate electrode (120) of the field effect transistor (114) or integrated into the gate electrode (120) of the field effect transistor (114), and • - at least one control device (146), the control device (146) being configured for applying operation parameters to the field effect transistor (114) and for monitoring at least one signal value with the field effect transistor (114); • ii. at least one parameter selection step comprising selecting a set of operation parameters of the field effect transistor (114) for at least one subsequent measurement step, the parameter selection step comprising performing a plurality of evaluation measurements with the field effect transistor (114) by using various sets of operation parameter candidates and by selecting the set of operation parameters in accordance with at least one optimization criterion monitored during the evaluation measurements; and • iii. at least one measurement step comprising detecting the concentration of the analyte by applying the set of operation parameters selected in step ii. to the field effect transistor (114) and by determining at least one signal value with the field effect transistor (114). Further, a sensor device (110) for determining the concentration of at least one analyte in a sample (112) is proposed.
The invention relates to a laboratory sample container carrier handling apparatus (1) comprising a revolving device (2) and a guiding surface (S), wherein an entry segment (EP) of the guiding surface (S) is adapted to smoothly receive a laboratory sample container carrier (3). The invention further relates to a laboratory automation system (100) comprising such a laboratory sample container carrier handling apparatus (1) and to a use of such a laboratory sample container carrier handling apparatus (1) for handling a laboratory sample container carrier (3) in, in particular such, a laboratory automation system (100).
G01N 35/04 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations - Details of the conveyor system
17.
A NOVEL ANTIBODY FOR DETECTION OF AMYLOID BETA 42 (AΒ42)
The present invention relates to a monoclonal antibody or an antigen-binding fragment thereof specifically binding to Aß42 with advantageous features for Aß42 detection in vitro using immunoassays. Also provided is a polynucleotide or a set of polynucleotides encoding the same and a vector comprising said polynucleotide(s). Further provided is a host cell comprising the polynucleotide(s) and a corresponding production process using this host cell. Also provided herein are uses and methods employing the monoclonal antibody or an antigen-binding fragment thereof specifically binding to Aß42 as provided herein.
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
18.
METHOD FOR CHARACTERIZATION OF A MASS SPECTROMETRY INSTRUMENT COMPRISING AT LEAST ONE MASS ANALYZING CELL
A method for characterization of a mass spectrometry instrument (100) comprising at least one mass analyzing cell (102, 104, 106) is proposed. The method comprising the steps of analyzing a sample (110) comprising at least one substance having a known molecular weight by means of the mass spectrometry instrument (100) so as to provide a mass spectrum (116, 118, 144, 146) of the sample (110), determining an outer envelope and an inner envelope of the mass spectrum (116, 118, 144, 146), calculating a squared difference between the outer envelope and the inner envelope, and determining a deviation of the calculated squared difference from a theoretical mass to charge ratio value of the substance.
Embodiments of the present disclosure relate to test result level based analysis. Some embodiments of the present disclosure provide a computer-implemented method. The method comprises obtaining a plurality of test result levels corresponding to a plurality of medical indicators of a patient, each test result level indicating that a quantitative test result of a corresponding medical indicator falls within one of a plurality of predetermined quantitative ranges; obtaining a plurality of reference test result levels corresponding to the plurality of medical indicators associated with a reference case, each reference test result level indicating that a quantitative reference test result of a corresponding medical indicator falls within one of the plurality of predetermined quantitative ranges; and determining a similarity between a medical condition of the patient and a reference medical condition associated with the reference case at least based on the plurality of test result levels and the plurality of reference test result levels. Through the solution, by means of test result level based analysis, it can protect the patient's privacy and obtain an accurate interpretation for the patient.
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
Tb0TTT. The present invention thus provides an automated analysis device with which it is possible to reduce the consumption of consumables that occurs when a reagent is registered, in comparison with a conventional device.
In a first aspect, the invention relates to a method for preparing a magnetic bead comprising at least one magnetic particle (M) and a silica coating, wherein the silica coating comprises at least two silica layers, the method comprising steps (a) to (d), wherein at least one of steps (b), (c) and (d) is/are done under sonication, wherein sonication is done with an amplitude (peak-to-peak) in the range of from 50 to 250 µm. A second aspect of the invention is related to a magnetic bead comprising (i) at least one magnetic particle (M) and (ii) a silica coating, wherein the silica coat-ing comprises at least two silica layers; wherein the magnetic bead is stable against 7.5 M hydrochlorid acid and has a metal (cation) leaching rate in 7.5 M hydrochloric acid in the range of from 0.1 to 10%, wherein the metal (cation) leaching is deter-mined according to a complex formation of Fe2+ with bathophenanthroline according to Reference Example 8.2. In a third aspect, the invention relates to a functionalized magnetic bead comprising at least one, magnetic bead according to the second aspect, wherein an outer silica layer is functionalized with at least one group selected from the group consisting of amino group, azide group, alkyne group, carboxyl group, thiol group, epoxy group, aryl group and alkyl group. A fourth aspect of the invention is directed to a process for functionalizing a magnetic bead according to the second aspect comprising at least one magnetic particle (M) and a silica coating, wherein the silica coating comprises at least two silica layers. A fifth aspect of the invention is related to a method for preparing magnetic Fe3O4 supra particles and a sixth aspect relates to the use of a magnetic bead according to the second aspect or of a functionalized according to the fourth aspect for immobilization of acid stable biocatalysts or for solid-phase organic synthesis using acid-stable linker.
H01F 1/33 - Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties of inorganic materials characterised by their coercivity of soft-magnetic materials metallic particles having oxide skin
H01F 1/34 - Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties of inorganic materials characterised by their coercivity of soft-magnetic materials non-metallic substances, e.g. ferrites
H01F 1/00 - Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
22.
METHOD FOR DETERMINING AN ANALYTE OF INTEREST BY FREQUENCY DETECTION
The present invention relates to a method for determining an analyte of interest by frequency detection and the use thereof, a modified nanopore, an analyzing system, a kit and the uses thereof.
The present disclosure pertains to a method for operating a laboratory automation system (1), the laboratory automation system (1) comprising a carrier (10) comprising a reception place (11) for receiving a sample container (12) configured to contain a sample to be analyzed by a laboratory device (13); a placement device (14) configured to pick and place the sample container (12); an imaging device (15); and a data processing device (16) comprising at least one processor (17) and a memory (18). The method comprises detecting an image of the reception place (11) by the imaging device (15); determining whether the reception place (11) is free for receiving the sample container (12) and the reception place (11) is configured to receive the sample container (12), by applying a machine learning algorithm for image analysis of the image of the reception place (11) in the data processing device (16); and placing the sample container (12) in the reception place (11) by the placement device (14) if the reception place (11) is determined as free and configured to receive the sample container (12). Further, a laboratory automation system (1) is disclosed.
G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor
The invention relates in a first aspect to an azadibenzocyclooctyne derivative according to formula (I) or a salt thereof having specific substituents at the benzo rings of the DIBAC structure and having specific substituents connected to the nitrogen atom of the DIBAC structure. A second aspect of the invention is directed to a conjugate of formula (II), wherein a substituent R6nn-Z-. A third aspect of the invention relates to a method for the modification of a target molecule, wherein a conjugate according to the second aspect is reacted with a target molecule comprising a 1,3-dipole group or a 1,3-(hetero)diene group. In a fourth aspect, the invention is directed to the use of the conjugate according to the second aspect for bioorthogonal labeling and/or modification of a target molecule. A fifth aspect of the invention relates to a modified target molecule comprising the reaction product of a conjugate according to the second aspect and a target molecule comprising a 1,3-dipole group or a 1,3-(hetero)diene group, obtained or obtainable from the method of the third aspect. In a sixth aspect, the invention is related to a kit comprising a modified target molecule according to the fifth aspect as detector reagent and a suitable capture reagent.
C07D 225/08 - Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with two six-membered rings
A61K 47/50 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
25.
NOVEL MONOCLONAL ANTIBODIES DIRECTED AGAINST L-THYROXINE AND DIAGNOSTIC USES THEREOF
The present invention provides a novel monoclonal antibody specifically binding to L-Thyroxine (T4) and compositions and kits comprising such antibodies. Furthermore, provided are polynucleotides encoding such monoclonal antibodies, host cells expressing said antibodies, methods of producing such antibodies and diagnostic methods using such monoclonal antibodies. The monoclonal antibody of the invention comprises a heavy chain variable domain (VH) comprising V or A in position 33; Y in position 50; W in position 52; I in position 98, G, A or V in position 99; Y in position 100; and I in position 100b; and a light chain variable domain (VL) comprising amino acids H or Y in position 28; N or K in position 29; W in position 32; G or A in position 91; Y, W or F in position 92; S or T in position 93;Y or F in position 95b; N, S, T or Q in position 95c; and H in position 96, wherein the positions of the amino acids in the VH and the VL are indicated according to the Kabat numbering scheme, respectively.
The present invention relates to monoclonal antibodies binding to the Receptor Binding Domain of the Spike protein of SARS-CoV-2 virus, nucleic acids encoding said antibody, host cells producing the same, compositions and kits comprising said antibodies, method of detecting SARS-CoV-2 virus in a sample comprising using said antibodies and methods of using said antibodies in immunoassays.
The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being MR-proADM, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: sFlt-1, GDF15 and ESM1, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being MR-proADM and a second biomarker selected from the group consisting of: sFlt-1, GDF15 and ESM1, or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
An analytical system (100, 100') comprising a mass spectrometer (60) and an ionization source (61) coupled to the mass spectrometer (60) is herein disclosed. The analytical system (100, 100') further comprises an analytical fluidic system (10, 10') connectable to the ionization source (61) via a downstream valve (20) for infusing samples into the mass spectrometer (60) via the ionization source (61), a downstream pump (40) fluidically connectable to the ionization source (61) via the downstream valve (20), where the downstream pump (40) is fluidically connected to a plurality of fluid containers comprising respective fluids (41, 42, 43, 44), the fluids comprising at least one concentrated composition (44) for calibrating the mass spectrometer (60) and at least one diluent (42, 43) for diluting the at least one concentrated composition (44). The analytical system(100, 100') further comprises a controller (90) configured to control the downstream pump (40) in order to obtain at least one diluted composition (45) by automatically mixing at least one concentrated composition (44) with at least one diluent (42, 43) with a predetermined dilution factor, to infuse the at least one diluted composition (45) into the ionization source (61), to obtain a mass spectrum (62) of the at least one diluted composition (45) and to execute a calibration (63) of the mass spectrometer (60) based on an assessment (64) of the mass spectrum (62). A respective automated analytical method comprising calibration of a mass spectrometer (60), like mass axis check and/or adjustment, with selected chemical compositions is herein also disclosed.
H01J 49/04 - Arrangements for introducing or extracting samples to be analysed, e.g. vacuum locks; Arrangements for external adjustment of electron- or ion-optical components
The present invention relates to a composition comprising (i) cesium iodide, (ii) ethylamine and/or formic acid, and (iii) methanol and/or water. The present invention further relates to a method for calibrating a mass spectrometry (MS) device comprising (I) determining a mass spectrum of a composition as specified; and (II) calibrating the MS device based on the mass spectrum determined in step (I). The present invention further relates to devices, kits, uses, and methods related thereto.
A centering holder (112) for centering and holding one sample tube (114) the centering holder (112) being adaptable to sample tubes (114) having different diameters is disclosed. The centering holder (112) comprises: at least two coupled centering fingers (122) arranged and configured to adapt to the diameter of the sample tube (112) and for applying a centering force on-to the sample tube (114) in a direction towards a center axis (124) of the centering holder (112), wherein each of the centering fingers (122) comprises at least one rod element (126) and at least one sleeve (128), wherein the sleeve (128 at least partially surrounds the rod element (126), wherein the sleeve (128) is configured for physically contacting the sample tube (114) thereby transferring the centering force onto the sample tube (114); and at least one base element (132) configured for supporting the at least two rod elements (126) of the centering fingers (122). Further, a sample handling system (110) is disclosed.
The present invention relates to a method for determining at least one analyte of interest. The present invention further relates to a sample element, an inlet, a composition, a kit and the use thereof for determining at least one analyte of interest.
A computer implemented method for automated quality check of chromatographic and/or mass spectral data is disclosed. The method comprises the following steps: a) (110) providing processed chromatographic and/or mass spectral data obtained by at least one mass spectrometry device (112); b) (114) classifying quality of the chromatographic and/or mass spectral data by applying at least one trained machine learning model on the chromatographic and/or mass spectral data, wherein the trained machine learning model uses at least one regression model (116), wherein the trained machine learning model is trained on at least one training dataset comprising historical and/or semi- synthetic chromatographic and/or mass spectral data, wherein the trained machine learning model is an analyte-specific trained machine learning model.
The present invention is provided with: a first mechanism group 202 for use only in analysis of biochemical items; a second mechanism group 203 for use only in analysis of immunological items; a shared mechanism group 204 for use in analysis of both biochemical items and immunological items; and a control unit 116 that operates the second mechanism group 203 and the shared mechanism group 204 without operating the first mechanism groups 202 when analysis of biochemical items is not required, and operates the first mechanism group 202 and the shared mechanism group 204 without operating the second mechanism group 203 when analysis of immunological items is not required. Accordingly, provided are: an automatic analysis device capable of reducing waiting time of a user and running cost as compared to conventional products; and a method for operating the automatic analysis device.
The present invention comprises: a storage part for storing, in advance, a specimen container 103 in which a specimen is accommodated before measurement; a dispensing mechanism 4 for suctioning the specimen from the specimen container; an input unit for accepting a command to store an emergency specimen in the storage part; a control unit 7 for, after completion of a first action performed by the dispensing mechanism at the time at which the command is received, performing control so as not to start a prescribed second action subsequently performed by the dispensing mechanism; and a display unit for prompting a user to store the emergency specimen in the storage part. The storage part is provided with a first storage section for storing a normal specimen, and a second storage section for storing the emergency specimen. The control unit, after having performed control so that the second action is not started, then performs control such that the second storage section moves to a position at which the emergency specimen is to be inserted by the user. This makes it possible for an operation such as additional installation of a container to be carried out by an operator during an analysis action using an automatic analysis device comprising a disc-type container installation mechanism.
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor
G01N 35/02 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
35.
METHOD FOR DETERMINING LIFETIME OF AT LEAST ONE CHROMATOGRAPHY COLUMN
A computer implemented method (140) for determining lifetime of at least one chromatography column (116) of at least one chromatography device (110), wherein the method (140) comprises the following steps: i) receiving model input chromatography data via at least one communication interface (128); ii) determining at least one state variable indicative of lifetime of the chromatography column (116) using at least one data driven model based on the model input chromatography data using at least one processing device (130); iii) evaluating the determined state variable thereby determining information about lifetime by using the processing device (130), wherein the evaluation comprises comparing the determined state variable to at least one threshold. Further, a test system (112), a computer program and a method for operating a chromatography column (116) are disclosed.
The present invention is provided with: one or more mechanisms used in analysis of a specimen; a main cover 21 covering at least one of the mechanisms; a reagent cover 22; a specimen cover 23; and opening/closing sensors 21a, 22a, 23a for detecting opening or closing of the main cover 21, the reagent cover 22, and the specimen cover 23. A control unit 80 causes a display unit 11 to display guidance for prompting a user to perform an operation required for analysis when the opening/closing sensors 21a, 22a, 23a detect opening of the main cover 21, the reagent cover 22, and the specimen cover 23. Accordingly, provided are an automatic analysis device and a guidance method used in the automatic analysis device, which are capable of reducing skipping of a procedure by a user as compared to conventional devices and methods.
An active centering device (112) for actively centering a sample holder (114) at at least one centering position in a sample handling system (110) is disclosed. The active centering device (112) comprises at least one gripper (120) with at least two centering gripper fingers (122) for gripping the at least one sample holder (114). The active centering device (112) further comprises at least one gear (124), at least one spring (126) and at least one motor (128) for driving the gripper (120), wherein the motor (128) is configured for driving the gripper (120) by transmitting a movement of the motor (128) via the at least one spring (126) and via the at least one gear (124) onto the centering gripper fingers (122). Further disclosed are a sample handling system (110), a centering method (150) and a handling method (160).
G01N 35/04 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations - Details of the conveyor system
39.
A TARGET FOR USE IN A LASER DESORPTION MASS SPECTROMETER
A target (110) for use in a laser desorption mass spectrometer is disclosed. The target (110) has at least one surface (112). wherein the surface (112) is covered at least partially with at least one layer (114), wherein the layer (114) is a hydrogen comprising, silicon- incorporated amorphous carbon (a-C:H:Si) layer (116), wherein the a-C:H:Si layer (116) comprises: · 40 at.% to 80 at.% of carbon; · 1 at.% to 20 at.% of hydrogen; and · 10 at.% to 40 at.% of silicon.
H01J 49/04 - Arrangements for introducing or extracting samples to be analysed, e.g. vacuum locks; Arrangements for external adjustment of electron- or ion-optical components
40.
TRANSFER DEVICE FOR TRANSFERRING SAMPLE CONTAINERS IN A SAMPLE HANDLING SYSTEM
A transfer device (110) for transferring sample containers in a sample handling system (112) is disclosed. The transfer device (110) comprises: - at least one transport device (114) comprising an array (116) of electromagnetic actuators (118), specifically electromagnetic actuators (118) comprising electromagnetic coils (120); - at least one moving unit (122) comprising at least one permanent magnet (124), wherein the moving unit (122) is movable in at least one movement plane (126), specifically in at least one movement plane (126) of the moving unit (122) defined by at least two moving directions (128), through the array (116) by magnetic interaction of the permanent magnet (124) with the electromagnetic actuators (118); and - at least one gripper unit (130) for positioning at least one of the sample containers, wherein the gripper unit (130) is movable in at least one gripping direction (132) essentially perpendicular to the movement plane (126), wherein the gripping unit (130) is attached to the moving unit (122). Further disclosed is a sample handling system (112) for handling a plurality of sample containers and a method for transferring sample containers in a sample handling system (112).
Provided is a diagnosis system for diagnosing a sensor that is provided to an automated analysis device and that outputs an analog electrical signal, the diagnosis system comprising: a memory for storing data of the electrical signals outputted by the sensor as well as the replacement history of the sensor; and a processing device for processing the data recorded in the memory. The processing device: reads out, from the memory, data of a set reference period, from among pieces of data of the electrical signal outputted by a sensor which was used in the past at the automated analysis device; computes a statistic for the data of the reference period; reads out, from the memory, data recorded in a set evaluation period, from among data pieces of the electrical signal outputted by a sensor to be diagnosed which is being used at the automated analysis device; computes a statistic for the data of the evaluation period; and assesses abnormality of the sensor to be diagnosed on the basis of the disparity found from the statistic for the reference period and the statistic for the evaluation period.
A method for detecting at least one analyte (110) in a sample (112) is disclosed. The method comprises the following steps: a) providing at least one sample (112) having at least one analyte (110); b) incubating the sample (112) with microparticles (118) having at least one surface (120) whereby the analyte (110) is adsorbed on the surface (120) of the microparticles (118) and an analyte-microparticle-complex (122) is formed; c) providing at least one fiber sheet material (128) having at least one tip (130) and contacting the tip (130) of the fiber sheet material (128) to the sample (112) comprising the analyte-microparticle-complex (122), whereby at least the analyte-microparticle-complex (122) is sucked into the tip (130) of the fiber sheet material (128); d) contacting the tip (130) of the fiber sheet material (128) to a port of an analytical device; e) adding an extracting solvent (138) to the fiber sheet material (128) and ap¬ plying an electrical voltage to the fiber sheet material (128) whereby ions of the analyte (110) are generated and are expelled from the tip (130) of the fiber sheet material (128); and f) detecting the at least one analyte (110) with the analytical device (134).
The present invention relates to diagnostic test and technology. In particular, it relates to the present invention relates to a method for determining an analyte suspected to be present in a sample comprising (a) contacting said sample with (i) a first binding agent which is capable of specifically binding to the analyte and which is immobilized on a solid support and (ii) a second binding agent which is capable of specifically binding to the analyte and which is capable of reversibly binding at least one detectable label, wherein said first and/or second binding agent is linked to an linking agent which is capable of covalently binding the at least one reversibly bound detectable label to the solid support when the first and second binding agents are in physical proximity, for a time and under conditions which allow specific binding of the analyte to the first and the second binding agent such that an complex of first binding agent, analyte and second binding agent is formed, and which allow for covalently binding the at least one detectable label to the solid support, and (b) removing the complex of first binding agent, analyte and second binding agent from the solid support such that the solid support having covalently bound the at least one detectable label remains, and (c) detecting the at least one covalently bound detectable label on the solid support whereby the analyte is determined. The present invention also relates to a device for determining an analyte suspected to be present in a sample, to the use of the device of the invention for determining an analyte suspected to be present in a sample in said sample, and to a kit for determining an analyte suspected to be present in a sample.
The present invention relates to a method of determining an analyte in a sample by mass spectrometry (MS), the method comprising (a) admixing a pre-determined amount of internal calibrator to said sample, wherein said internal calibrator comprises at least two non-identical isotopologues of the analyte at predetermined amounts; (b) determining MS signals of ions generated from said analyte (analyte signal) and from said at least two isotopologues (isotopologue signals); (c) providing a calibration based on the analyte signal and the isotopologue signals determined in step (b); and (d) determining said analyte based on the calibration provided in step (c). Further, the present invention relates to devices, systems, and uses related thereto.
The present invention relates to diagnostic test and technology. In particular, it relates to the present invention relates to a method for determining an analyte suspected to be present in a sample comprising contacting said sample with a sensor element comprising i) an anchor layer which is present on a solid support, ii) a first binding agent which is capable of specifically binding to the analyte, which is anchored in the anchor layer and which comprises at least one detectable label, and iii) a second binding agent which is capable of specifically binding to the analyte when bound to the first binding agent and which is immobilized on the solid support, for a time and under conditions which allow for specific binding of the analyte suspected to be present in the sample to the first binding agent and specific binding of the second binding agent to the analyte bound to the first binding agent and detecting the formation of the complex of first binding agent, analyte and second binding agent whereby the analyte is determined. Moreover, provided is a device for determining an analyte suspected to be present in a sample and the use thereof for determining an analyte suspected to be present in a sample in said sample. Moreover, the present invention contemplates a kit for determining an analyte suspected to be present in a sample.
The present invention relates to diagnostic test and technology. In particular, it relates to a method for determining an analyte suspected to be present in a sample comprising contacting said sample with at least one sensor element comprising at least one binding agent which is capable of specifically binding to the analyte and which comprises at least one magnetic label; and in functional proximity thereto a magnetic tunnel junction generating a signal which is altered upon binding of the analyte to the binding agent for a time and under conditions which allow for specific binding of the analyte suspected to be present in the sample to the at least one binding agent, measuring an altered signal generated by the magnetic tunnel junction upon analyte binding to the at least one binding agent comprising the at least one magnetic label, and determining the analyte based on the altered signal which is generated by the magnetic tunnel junction. The present invention further relates to a device for determining an analyte suspected to be present in a sample and for using such a device. Moreover, the present invention furthermore relates to an aptamer which is capable of specifically binding to an analyte and which comprises at least one magnetic label and a method for identifying such an aptamer. Finally, the invention relates to a kit for determining an analyte suspected to be present in a sample.
The present invention concerns the field of diagnostics. In particular, it relates to a method for determining an analyte suspected to be present in a sample comprising contacting said sample with a sensor element comprising an anchor layer which is present on a solid support, a first binding agent which is capable of specifically binding to the analyte, which is anchored in the anchor layer, a second binding agent which is capable of specifically binding to the analyte when bound to the first binding agent and which is immobilized on the solid support, said second binding agent comprising at least one magnetic label, and a magnetic tunnel junction in functional proximity to the second binding agent which generates a signal elicited in proximity to the at least one magnetic label of the second binding agent, for a time and under conditions which allow for specific binding of the analyte suspected to be present in the sample to the first binding agent and specific binding of the second binding agent to the analyte bound to the first binding agent and detecting the formation the complex of first binding agent, analyte and second binding agent based on an altered signal which is generated by the magnetic tunnel junction whereby the analyte is determined. The present invention, further, relates to a device and a kit for determining an analyte suspected to be present in a sample and to the use of said device for determining an analyte suspected to be present in a sample.
The present invention relates to diagnostic test and technology. In particular, the present invention relates to a method for determining an analyte suspected to be present in a sample comprising contacting said sample with a sensor element comprising an anchor layer which is present on a solid support, a first binding agent which is capable of specifically binding to the analyte, which is anchored in the anchor layer and which comprises at least one magnetic label, wherein said at least one magnetic label is located within the anchor layer, a second binding agent which is capable of specifically binding to the analyte when bound to the first binding agent and which is immobilized on the solid support, and a magnetic tunnel junction in functional proximity to the second binding agent which generates a signal elicited in proximity to the at least one magnetic label of the first binding agent, for a time and under conditions which allow for specific binding of the analyte suspected to be present in the sample to the first binding agent and specific binding of the second binding agent to the analyte bound to the first binding agent and detecting the formation the complex of first binding agent, analyte and second binding agent based on the signal which is generated by the magnetic tunnel junction whereby the analyte is determined. Moreover, provided is a device for determining an analyte suspected to be present in a sample and the use thereof for determining an analyte suspected to be present in a sample in said sample. Moreover, the present invention contemplates a kit for determining an analyte suspected to be present in a sample.
The present invention relates to a method of determining an analyte in a sample, said method comprising (a) contacting said sample with (i) a binding compound binding to said analyte, said binding compound comprising a binding agent and a first partner of an affinity pair (first affinity partner); and (ii) a second partner of the affinity pair (second affinity partner) coupled to a solid surface, to an indicator, and/or to a second binding agent; and (b) determining said analyte based on complexes formed in step (a); wherein one of said first affinity partner and said second affinity partner is a polypeptide comprising the amino acid sequence of SEQ ID NO:l or a sequence at least 50% identical thereto, and wherein the other of said first affinity partner and said second affinity partner is a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or a sequence at least 50% identical thereto, the present invention also relates to a polypeptide comprising an amino acid sequence as specified in SEQ ID NO:l or a sequence at least 50% identical thereto, wherein the amino acid at the position corresponding to position 77 in SEQ ID NO: 1 is not a histidine; and to a polypeptide comprising an amino acid sequence as specified in SEQ ID NO:2 or a sequence at least 50% identical thereto, wherein (i) the amino acid at the position corresponding to position 17 in SEQ ID NO:2 is not a cysteine, in an embodiment is alanine, serine, leucine, isoleucine, or glycine and/or (ii) said polypeptide further comprises at least one functional peptide; and to fusion polypeptides, polypeptide complexes, polynucleotides and kit related to the aforesaid.
A time tracking device (112) for monitoring system performance of at least one laboratory instrument is proposed. The time tracking device (112) comprises at least one support structure (114). The time tracking device (112) further comprises at least one electronics unit (116) and at least one motion sensor (118) housed by the support structure (114). The motion sensor (118) is configured for detecting a change of motion and/or orientation of the time tracking device (112). The electronics unit (116) is configured for measuring time, wherein a time measurement is initiated by detecting a change of motion and/or orientation of the time tracking device (112) and is terminated by detecting a subsequent change of motion and/or orientation of the time tracking device (112). The support structure (114) is a polygonal support structure (114) comprising a plurality of faces (120), wherein the support structure (114) comprises at least two interactive faces (136). Each of the interactive faces (136) comprises at least one user interface (138) comprising at least one display device (140). Each of the interactive faces (136) is configured for displaying at least one status indication (171) of the laboratory instrument, wherein the interactive face (136) matching a current status of the laboratory instrument is selectable by a user via changing motion and/or orientation of the time tracking device (112). The time tracking device (112) is configured for providing data relating to the measured time via at least one communication interface (172).
G06Q 10/08 - Logistics, e.g. warehousing, loading or distribution; Inventory or stock management
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G04F 8/00 - Apparatus for measuring unknown time intervals by electromechanical means
An analyzer system (110) is disclosed. The analyzer system (110) comprises: • at least one mass spectrometry device (112) having at least one electrospray ion source nozzle (114); • at least one liquid supply (116), wherein the liquid supply (116) is configured for providing at least one liquid having at least one analyte; • at least one gas supply (118), wherein the gas supply (118) is configured for providing at least one gas; and • at least one dopand gas supply (120), wherein the dopand gas supply (120) is configured for providing at least one chemical dopand gas having at least one chemical dopand (122) to the analyte provided by the liquid supply (116); wherein the liquid supply (116) and the gas supply (118) are coupled to the mass spectrometry device (112) via the electrospray ion source nozzle (114), wherein the dopand gas supply (120) is connected to the gas supply (118).
A computer-implemented method is provided that includes transmitting, by a master node to a plurality of computing nodes, definition information about an initial medical validation model (410); performing, by the master node, a federated learning process together with the plurality of computing nodes (420), to jointly train the initial medical validation model using respective processed local training datasets available at the plurality of computing nodes, the respective local training datasets being processed by the plurality of computing nodes based on the definition information; and determining, by the master node, a final medical validation model based on a result of the federated learning process (430). Through the solution, by means of federated learning, it addresses the data security and privacy concerns from local sites owning.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
53.
sFRP4 AS BLOOD BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF ADENOMYOSIS
The present invention relates to methods of assessing whether a patient has adenomyosis or is at risk of developing adenomyosis, to methods of selecting a patient for therapy of adenomyosis, and methods of monitoring a patient suffering from adenomyosis or being treated for adenomyosis, by determining the amount or concentration of sFRP4 in a sample of the patient, and comparing the determined amount or concentration to a reference.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
54.
AUTOMATIC REGISTRATION OF AT LEAST ONE DEVICE IN A LABORATORY SYSTEM
A computer-implemented method of automatic registration of at least one device (110) in a laboratory system (112) is proposed. The laboratory system (112) comprises a plurality of laboratory devices (116). The method comprises the following steps: i) at least one initializing step (118), wherein the initializing step (118) comprises transmitting from the device (110) to be registered device specific information to at least one laboratory communication and managing unit (120) via at least one first communication interface; ii) at least one device configuration step (124), wherein the device configuration step (124) comprises the laboratory communication and managing unit (126) requesting, based on the device specific information, a solution specific configuration from at least one remote infrastructure (126) via at least one second communication interface, wherein the device configuration step (124) comprises receiving the solution specific configuration from the remote infrastructure (126) by the laboratory communication and managing unit (120) via the second communication interface and transmitting the solution specific configuration from the laboratory communication and managing unit (120) to the device (110) to be registered via the first communication interface, wherein the solution specific configuration is based on the device specific information and configuration information about the laboratory system (112); iii) at least one laboratory configuration step (134), wherein the laboratory configuration step (134) comprises transmitting at least one request from the laboratory communication and managing unit (120) comprising updated solution specific configuration to the laboratory devices (116) of the laboratory system (112) via their respective communication interface, wherein the updated solution specific configuration comprises information about the device (110) to be registered and changes due to addition of said device (110) to the laboratory system (112), wherein the laboratory configuration step (134) further comprises providing the updated solution specific configuration to the remote infrastructure (126).
G16H 40/40 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades
G16H 40/60 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
55.
METHOD FOR OPERATING A LABORATORY AUTOMATION SYSTEM, LABORATORY AUTOMATION SYSTEM, AND LABORATORY IN-VITRO DIAGNOSTIC SYSTEM
Roche Diagnostics GmbH et al. R75170WO Abstract The present disclosure refers to a method for operating a laboratory automation sys- tem (407), comprising a plurality of devices (401), a transport system (404), a plurality of transfer devices (402); a portable device; and a plurality of data communication modules.5 The method comprises: receiving device information for the plurality of devices (401) in the portable device, the device information being indicative a device identification; receiving a first user input in the portable device, the user input being indicative of a selection of a first device (401) from the plurality of devices (401); in response to receiving the first user input, pairing the first device (401) with the transport system (404) for data communication in op-10 eration of the first device (401) for at least one of sample pre-analytics and sample analysis; and providing first pairing information in the portable device, the first paring information being indicative of the first device (401) and the distribution system being paired successfully. Fur- ther, a laboratory automation system (407) and a laboratory in-vitro diagnostic system are provided. (Fig. 4a)15
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G01N 35/04 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations - Details of the conveyor system
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor
56.
MONITORING DEVICE FOR MONITORING A SAMPLE HANDLING SYSTEM
A monitoring device (110) for monitoring a sample handling system (112) is disclosed. The monitoring device (110) comprises: at least one sliding unit (114) comprising at least one sliding surface (116), wherein the sliding unit (114) is configured for sliding over at least one sample transport device (118) of the sample handling system (112); and at least one imaging streaming unit (120) comprising at least one camera (122), wherein the camera (122) is configured for capturing a plurality of images, wherein the imaging streaming unit (120) comprises at least one imaging communication interface (124) for providing the plurality of captured images to at least one transport control system (126) of the sample handling system (112). Further disclosed is a transport control system (126) for controlling transport of a plurality of sample container holders (150) of a sample handling system (112), a sample handling system (112) for handling a plurality of samples (160), a method for identifying at least one obstacle (156), a method for determining a distance between at least one obstacle (156) and a monitoring device (110) and a method for controlling a monitoring device (110) and further computer programs and computer-readable storage media for performing the methods.
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor
G01N 35/04 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations - Details of the conveyor system
B65G 54/02 - Non-mechanical conveyors not otherwise provided for electrostatic, electric, or magnetic
G01C 3/00 - Measuring distances in line of sight; Optical rangefinders
The present invention concerns the field of diagnostics. Specifically, it relates to methods, also computer-implemented methods, for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being ESM-1, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is Creatinine or a Cystatin C, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection. The invention also relates to the use of said biomarkers, devices and a kits.
The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being STREM1, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: Aspartate aminotransferase, Bilirubin, ESM-1, HBP (Heparin-binding protein), a cardiac Troponin, Alanine aminotransferase, and IL6, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being STREM1 and a second biomarker selected from the group consisting of: Aspartate aminotransferase, Bilirubin, ESM- 1, HBP (Heparin-binding protein), a cardiac Troponin, Alanine aminotransferase, and IL6 or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being sFlt1, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: Cystatin C, IGFBP7, a cardiac Troponin, Creatinine, sTREM1, PCT and Bilirubin, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being sFlt1 and a second biomarker selected from the group consisting of: Cystatin C, IGFBP7, a cardiac Troponin, Creatinine, sTREM1, PCT and Bilirubin, or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being PCT, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: a cardiac Troponin, Creatinine, a BNP -type peptide, sTREMl, ESM-1, Haptoglobin, Heparin binding protein (HBP) and Aspartate aminotransferase, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being PCT and a second biomarker selected from the group consisting of: a cardiac Troponin, Creatinine, a BNP -type peptide, sTREMl, ESM-1, Haptoglobin, Heparin binding protein (HBP) and Aspartate aminotransferase, or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being Presepsin, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: GDF-15, Creatinine, sF1t1, IGFBP7, sTREM1, Cystatin C and PSP (Pancreatic Stone Protein), comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being Presepsin and a second biomarker selected from the group consisting of: GDF-15, Creatinine, sF1t1, IGFBP7, sTREM1, Cystatin C and PSP (Pancreatic Stone Protein), or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
The present invention relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being GDF-15, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: sFLT1, Cystatin C, IGFBP-7, Bilirubin, ESM-1, sTREM-1, Procalcitonin, cardiac Troponin, BNP-type peptide, Alanine aminotransferase, and Aspartate aminotransferase, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being GDF-15 and a second biomarker selected from the group consisting of sFLT1, Cystatin C, IGFBP-7, Bilirubin, ESM-1, sTREM-1, Procalcitonin, cardiac Troponin, BNP-type peptide, Alanine aminotransferase, and Aspartate aminotransferase or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being IGFBP7, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: PCT, IL6, a cardiac Troponin, Albumin, CRP, Bilirubin, Ferritin, ESM-1, Aspartate aminotransferase, a BNP-type peptide, Alanine aminotransferase, Creatinine, and suPAR, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being IGFBP7 and a second biomarker selected from the group consisting of: PCT, IL6, a cardiac Troponin, Albumin, CRP, Bilirubin, Ferritin, ESM-1, Aspartate aminotransferase, a BNP-type peptide, Alanine aminotransferase, Creatinine, and suPAR, or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
The present invention concerns the field of diagnostics. Specifically. it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject. said first biomarker being NGAL. determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: HBP (Heparin-binding protein). Aspartate aminotransferase. Bilirubin. Alanine aminotransferase. ESM-1 and a BNP-type peptide. comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers. and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being NGAL and a second biomarker selected from the group consisting of: HBP (Heparin-binding protein). Aspartate aminotransferase. Bilirubin. Alanine aminotransferase. ESM-1 and a BNP-type peptide. or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover. the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being IL-6, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is Creatinine or a cardiac Troponin, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being IL-6 and a second biomarker being a cardiac Troponin or Creatinine or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
This information processing device includes a first determining unit which inputs, into a first learned model, information relating to total protein (TP), cholinesterase (ChE), total cholesterol (TC), creatinine (CREA), and creatine phosphokinase (CPK), from information relating to a blood test of a subject, and which outputs information relating to whether a thyroid stimulating hormone (TSH) of the subject is in a range requiring treatment.
G01N 33/92 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol
G16H 50/00 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
A method for processing an image (130) of a liquid sample (110), comprising: obtaining an image (130) of the liquid sample (110) captured by a target capturing device (120), (402); calibrating the image (130) of the liquid sample (110) using a calibration function (404), the calibration function being determined based on a pair of images of a color reference object, the pair of images comprising a target image captured by the target capturing device (120) and a corresponding baseline image; and determining a sub-image (160) corresponding to a target portion from the calibrated image (150) for classification (406). Method and system (140) for quality control are also provided. Through the solution, the performance of sample quality control may be improved.
The present invention relates to methods of assessing whether a patient has endometriosis or is at risk of developing endometriosis, to methods of selecting a patient for therapy, and method of monitoring a patient suffering from endometriosis or being treated for endometriosis by determining the amount or concentration of SCF in a sample of the patient, and comparing the determined amount or concentration to a reference.
The present invention relates to methods of assessing whether a patient has endometriosis or is at risk of developing endometriosis and in particular early stages to methods of selecting a patient for therapy and to methods for monitoring disease progression in a patient suffering from endometriosis or being treated for endometriosis by determining the amount or concentration of PSP94 in a sample of the patient, and comparing the determined amount or concentration to a reference.
The present invention relates to chemical probes for the improved detection of cysteine in a test sample, preferably an aqueous test sample, as well as respective uses and kits.
A method of creating a secure collaborative analysis system for securely using a dataset from a plurality of laboratories (150) while ensuring confidentiality, integrity, and authenticity of input and result data among the plurality of collaborating laboratories (150) is presented. The plurality of laboratories (150) are communicatively connected to an execution environment. The method comprise creating a secure enclave (110) within the execution environment for data exchange and analysis, attestation of the execution environment and the secure enclave (110) to verify integrity and authenticity of the system, generating a random 12-byte character inside the secure enclave (110) to provide integrity protection for storing records in a database (130), and building a communication component to provide a means of secure communication between the plurality of laboratories (150) and the execution environment. The communication component comprises a trusted section within the secure enclave (110) and an unprotected section. The plurality of laboratories (150) communicate with the trusted part via a secure channel. The method further comprises detecting any unauthorized modification to the record stored in the database (130) outside of the secure enclave (110) by a records integrity component, storing the encrypted dataset in the persistent storage disk (120) received from the plurality of laboratories (150), retrieving the encrypted dataset inside the secure enclave (110), decrypting the encrypted dataset inside the secure enclave (110), providing the decrypted dataset to an analysis engine component within the secure enclave (110) for analysis, and providing results of that analysis to plurality of laboratories (150) in the secure manner.
G06F 21/62 - Protecting access to data via a platform, e.g. using keys or access control rules
G06F 21/74 - Protecting specific internal or peripheral components, in which the protection of a component leads to protection of the entire computer to assure secure computing or processing of information operating in dual or compartmented mode, i.e. at least one secure mode
An apparatus(210) for monitoring pathogen infection. The apparatus(210) comprises a ventilator(220) adapted to be coupled to a mask(130). The apparatus(210) comprises a monitoring component(230) coupled to the ventilator(220). The monitoring component(230) is configured to detect a pathogen in substances exhaled by a user(150) wearing the mask(130) and generate information concerning the detection of the pathogen. The apparatus(210) comprises a communication component(240) coupled to the monitoring component(230). The communication component(240) is configured to transmit the generated information to a device(110).
The present disclosure relates to a computer implemented method of managing sample processing priorities in a diagnostic laboratory comprising at least one sample processing device (100) connected to a host system (200). The method comprises generating a communication message (20) between the host system (200) and the at least one sample processing device (100) related to a sample processing order (10) received in association with a sample, the message (20) comprising one of at least two priority identifiers (R, S) indicative of respective sample processing priorities from lower priority to higher priority according to the received sample processing order (10). The method further comprises identifying (30) the sample by the at least one sample processing device (100) and processing the sample (31, 32) by the at least one sample processing device (100) according to the sample processing priority (S, R) in the message (20). In case of receiving a subsequent request for change (40) of sample processing priority for the sample from a lower priority to a higher priority after transmission of the message (20) and before the sample is processed, the method comprises changing (50) the message (20) and processing the sample as a higher priority sample (31) instead of as a lower priority sample (32), wherein changing the message (20) comprises changing the lower priority identifier (R) to an identifier (CS) indicative of a change of priority but different from an equivalent higher priority identifier (S) in order to maintain the sample and the sample processing order uniquely identifiable and traceable by both the host system (200) and the at least one sample processing device (100). A respective system for managing sample processing priorities is herein also disclosed.
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
A reaction vessel (100) for a diagnostic analyzer (106) comprising a plurality of processing stations (108) is disclosed. The reaction vessel (100) comprises at least one sensor (110) configured to measure at least one physical parameter associated with at least one of the processing stations (108) of the diagnostic analyzer (106) when disposed at the at least one of the processing stations (108), a memory (112) configured to at least temporarily store at least one measurement value indicating the physical parameter provided by the sensor (110), a processing unit (114) configured to control the sensor (110) and to output meas- urement data including the measurement value from the memory (112), an interface (118) configured to provide communication of the processing unit (114) with an external elec- tronic device (120), a power source (126) configured to supply electric power to the sensor (110), the processing unit (114) and the memory (112). The reaction vessel (100) defines an internal volume (104). The sensor (110), the processing unit (114), the memory (112) and the interface (118) are arranged within the internal volume (104).
The present disclosure relates to a laboratory data management system (100) comprising a data source layer (10) comprising at least one laboratory device (11, 12, 13, 14, 15) as a data source, a data adapter layer (20) comprising at least one data source agent (21, 22, 23, 24, 25) configured to obtain data from the at least one data source and to convert the data from a data source format to a data- source independent format, a consumer layer (30) configured for installation and/or execution of consumer application software (31, 32, 33, 34), and a data management layer (40) between the data adapter layer (20) and the consumer layer (30). The data management layer (40) comprises a data storage (50) configured to store data 1-n converted by the at least one data source agent (21, 22, 23, 24, 25), at least one data manager (41, 42, 43, 44) programmed to execute instructions from the consumer application software (31, 32, 33, 34), which when executed cause the at least one data manager (41, 42, 43, 44) to select application-specific data in the data storage (50) and to make them accessible to a consumer via the consumer application software (31, 32, 33, 34) in a consumer format. The data adapter layer (20) and the data management layer (40) are arranged in a laboratory gateway (60) connected to the data- source layer (10) and to the consumer layer (30).
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor
A column device (116) for an automatic analyzer (100) is disclosed. The automatic analyzer (100) comprises a high performance liquid chromatography (HPLC) module (102). The HPLC module (102) comprises a fixation device (104) configured to automatically fix and release a chromatographic column (106). The column device (116) comprises a column jacket (118) and a capillary (120). The capillary comprises predetermined dimensions and is disposed within the column jacket (118). The column device (116) is configured to be installed at the HPLC module (102) by means of the fixation device (104). Further, an automatic analyzer (100) is disclosed.
The present invention relates to an in vitro method for assessing the risk of non-small cell lung carcinoma (NSCLC) disease progression for a subject classified to have stable disease under an ongoing NSCLC treatment regime. The method involves determining the level of CYFRA 21-1 and/or the level of CA 125 in a sample obtained from the subject; and comparing (i) the determined level of CYFRA 21-1 to a CYFRA 21-1 cut-off level, (ii) the determined level of CA 125 to a CA 125 cut-off level, or (iii) a score taking into account the determined level of CYFRA 21-1 and/or the determined level of CA 125 to a cut-off score. The method of the invention further allows for assessing whether the subject responds to the ongoing treatment and/or whether the treatment regime should be maintained or modified. The invention also provides for corresponding uses, computer-implemented methods and computer program products.
G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
The present invention relates to a clinical diagnostic system, a method for determining the presence or level of at least one analyte of interest in a biological sample, a kit and the uses thereof for efficiently and/or robust detection of an analyte of interest.
The invention relates to a support element for a modular transport plane with a plurality of transport module units (1) each comprising a driving surface assembly (4), wherein the support element has an upper support surface (55) configured to support the driving surface assemblies (4) of at least two neighboring transport module units (1), wherein the upper support surface (55) is provided with driving surface assembly interfaces (56) configured to engage with complementary interfaces of the supported driving surface assemblies (4), wherein the support element comprises a lower part (50) having a mounting structure and an upper part (51) having the upper support surface (55), wherein the upper part (51) is connected lengthwise to the lower part (50) via a connection structure (52), and wherein the connection structure (52) is configured to restrain a relative movement between the lower part (50) and the upper part (51) in the longitudinal direction of the support element and to allow a limited relative movement between the lower part (50) and the upper part (51) in a plane perpendicular to the longitudinal direction of the support element.. The invention further relates to a modular transport plane, to a laboratory distribution system, and to a laboratory automation system comprising a laboratory distribution system.
G01N 35/04 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations - Details of the conveyor system
80.
METHOD FOR DETECTING AN ANALYTE OF INTEREST IN A SAMPLE
The present invention relates to a method for determining at least one analyte of interest. The present invention further relates to a kit, a complex, a method to synthesize a complex and the use thereof for detecting the analyte of interest in the sample.
G01N 33/531 - Production of immunochemical test materials
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
81.
EVAPORATION-BASED SAMPLE PREPARATION WORKFLOW FOR MASS SPECTROMETRY
The present invention relates to a method for detecting and/or quantifying an analyte in a sample using mass spectrometry. The method of the invention comprises: extracting the analyte from the sample using solid phase extraction (SPE) so as to obtain an SPE extract comprising the analyte, concentrating the analyte, said concentrating comprising evaporating solvent from the SPE-extract; and detecting and/or quantifying the analyte in the sample using mass spectrometry.
G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
G01N 33/74 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
G01N 30/00 - Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography
82.
LC-MS METHOD FOR DETECTING AND QUANTIFYING 11-OXYGENATED STEROIDS
The present invention relates to a method for detecting and/or quantifying one or more steroids using mass spectrometry, said steroids comprising at least one 11-oxygenated steroids. The method of the invention comprises (i) extracting the one or more steroids from the sample using solid phase extraction (SPE) so as to obtain an SPE extract comprising the one or more steroids; (ii) concentrating the one or more steroids, said concentrating comprising evaporating solvent from the SPE-extract; and (iii) detecting or quantifying the one or more steroids in the sample using mass spectrometry.
A method for optimizing at least one parameter setting of at least one mass spectrometry device (110) operating at unit resolution is disclosed. The method comprises the following steps: a) determining at least one analyte detection window for detecting an analyte of interest with the mass spectrometry device (110), wherein the analyte detection window is defined by a central mass to charge ratio value of the analyte and a pre-defined width, wherein the central mass to charge ratio value of the analyte is set to a theoretical mass to charge ratio value of the analyte of interest having more than one decimal place and/or a mass to charge ratio value of the analyte of interest determined by a high resolution mass spectrometry measurement having more than one decimal place; b) determining at least one internal standard detection window for detecting an internal standard substance with the mass spectrometry device (110), wherein the internal standard detection window is defined by a central mass to charge ratio value of the internal standard substance and the pre-defined width, wherein the central mass to charge ratio value of the internal standard substance is set to a mass to charge ratio value of the internal standard substance calculated relative to the analyte of interest and having more than one decimal place and/or to a mass to charge ratio value of the internal standard substance determined by a high resolution mass spectrometry measurement having more than one decimal place.
The present invention relates to a method for providing a verified analyte measurement of a sample with a chromatography mass spectrometer device, said method comprising the following steps: a) admixing an interferent monitoring compound and, optionally an internal standard, to the sample; b) determining a chromatogram of the sample by acquiring a plurality of data points for signal intensities over time for said interferent monitoring compound, said analyte, and optionally said internal standard; and c) comparing a property of an interferent monitoring compound peak to a property of an internal standard peak and/or to a property of an analyte peak; and to methods and systems related thereto.
The present invention relates to a method, a diagnostic system, a dopant and the use thereof for the enhancement of detection of an analyte of interest by Cross Spray ESI mass spectrometry. The dopant is preferably a sulfone. The method involves two electrospray ionization sources for a two analytical flow streams in a gaseous form or aerosol. The second flow stream comprises a dopant or a derivatization reagent. The the first and the second analytical flow stream are intermixed and the presence or the level of an analyte of interest in the sample is determined with improved sensitivity using mass spectrometry.
A handheld diagnostic device (112), specifically for point-of-care applications, is disclosed. The handheld diagnostic device (112) comprises: a. at least one diagnostic measurement unit (118) configured for performing at least one diagnostic measurement, the diagnostic measurement unit (118) comprising at least one test element port (124) for determining at least one diagnostic parameter of at least one patient by using at least one diagnostic test element (114); b. at least one camera (120) configured for capturing at least one image of at least one wound (130) of the patient; and c. at least one control unit (122), the control unit (122) being configured for controlling the diagnostic measurement and for controlling the capturing of the image of the wound (130), wherein the control unit (122) is further configured for storing at least one measurement result of the diagnostic measurement and the at least one image in at least one database record of the patient. Further, a diagnostic system (110) and a diagnostic method are disclosed.
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
87.
MONITORING DEVICE FOR MONITORING AN ELECTRIC MOTOR IN A LABORATORY SYSTEM
A monitoring device (112) for monitoring an electric motor (114), specifically of a laboratory system (110), is disclosed. The monitoring device (112) comprises: A. at least one receiving unit (116) configured for receiving information on at least one amount of acceleration energy required for accelerating the electric motor (114) from at least one first motion state to at least one second motion state; B. at least one evaluation unit (122) configured for evaluating the information on the amount of acceleration energy and for determining at least one item of information on a wearing status of the electric motor (114). The acceleration energy comprises an acceleration energy which is at least one of dissipated, recuperated or released when decelerating the electric motor (114) from a rotating motion state to a stationary state. Further, a laboratory system (110), a method of monitoring an electric motor (114), a method of operating a laboratory system (110), computer programs and computer-readable storage media are disclosed.
H02P 29/024 - Detecting a fault condition, e.g. short circuit, locked rotor, open circuit or loss of load
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor
H02P 29/032 - Preventing damage to the motor, e.g. setting individual current limits for different drive conditions
H02P 3/06 - Arrangements for stopping or slowing electric motors, generators, or dynamo-electric converters for stopping or slowing an individual dynamo-electric motor or dynamo-electric converter
88.
DERIVATIZATION OF AT LEAST ONE ANALYTE OF INTEREST FOR MASS SPEC MEASUREMENTS IN PATIENT SAMPLES
The present invention relates to a method for determining the presence or level of an analyte of interest and the use thereof. Further, present invention relates to an analytical system, a sampling tube and the use of the sampling tube and a nucleophilic derivatization reagent.
The invention relates to a method for managing information dealing with a medical test for assessing a predetermined medical condition by means of a distributed system (100) comprising a plurality of communication devices (210, 312, 322, 410), the method comprising obtaining by a user communication device (210) information on an access code provided in a test-kit for assessing a predetermined medical condition, the user communication device (210) being configured for receiving and displaying messages addressed to a unique identifier. Further, the method comprises providing instructions relating to analysis of the medical sample. A negative analysis result is communicated to the user communication device (210) of the user. In case of a positive analysis result, consultation by a medical entity is established. Further aspects relate to a user communication device, a computer program product, a central server and a medical test-kit for use with the proposed method.
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 40/60 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
G16H 80/00 - ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
G16H 50/80 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
G01N 33/487 - Physical analysis of biological material of liquid biological material
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
The present invention relates to monoclonal antibodies binding to the nucleocapsid protein of SARS-CoV-2 virus, nucleic acids encoding said antibody, host cells producing the same, compositions and kits comprising said antibodies, as well as method od detecting SARS-CoV-2 virus in a sample comprising using said antibodies.
The present invention relates to an in vitro method for assessing cholangiocarcinoma in a patient sample, comprising the steps of: a) determining the level of tissue inhibitor of metalloproteinase-1 (TIMP1) in the patient sample, wherein the patient sample is selected from a group consisting of serum, plasma and whole blood sample from an individual, b) comparing the level of TIMP1 determined in step (a) with a reference level of TIMP1, and c) assessing cholangiocarcinoma in the patient sample by comparing the level determined in step (a) to the reference level of TIMP1, wherein an increased level of TIMP1 compared to the reference level of TIMP1 is indicative for cholangiocarcinoma in the patient sample. Further, the present invention relates to an in vitro method for assessing cholangiocarcinoma comprising TIMP1 and MMP2, the use of TIMP1 and optionally MMP2 in the in vitro assessment of CCA, and a kit for performing the said methods.
The present invention relates to a method, a diagnostic system, a kit and the use thereof for efficiently detection of an analyte of interest by nanoESI mass spectrometry.
Embodiments of the present disclosure relate to method and system for diagnostic analyzing. Some embodiments of the present disclosure provide a diagnostic analyzing system (1). The diagnostic analyzing system (1) comprises one or more analyzer instruments (10) and a monitoring system (20), e.g. a quality control monitoring system. The one or more analyzer instruments (10) designed for providing an analytical testing result, which is to be validated by the monitoring system (20) using a validation algorithm. Moreover, the monitoring system (20) may re-train the validation algorithm when a difference level between a live data set and a first training data set is greater than a threshold. Through the solution, it is possible to improve the accuracy of the validation algorithm.
The present invention relates to a method and the use thereof for for determining the level of Vitamin D and metabolites thereof. Further, it is an object of the present invention to provide a kit and the use thereof for determining the level of Vitamin D and metabolites thereof.
G01N 33/82 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins
95.
CIRCULATING TOTAL-NT-PROBNP (GLYCOSYLATED AND UNGLYCOSYLATED NT-PROBNP) AND ITS RATIO WITH NT-PROBNP (UNGLYCOSYLATED NT-PROBNP) IN THE ASSESSMENT OF ATRIAL FIBRILLATION
The present invention relates to a method for diagnosing atrial fibrillation in a subject, said method comprising the steps of a) determining the amount of total NT-proBNP in sample from the subject, b) determining the amount of unglycosylated NT-proBNP in a sample from the subject, c) calculating a score of the amounts determined in steps a) and b), d) comparing the calculated score with a reference score, and e) diagnosing atrial fibrillation in a subject.
The present invention relates to bacterial pilus protein complex FimGt-DsF stabilized protein complexes for producing phagemids or filamentous phages, and methods for use of these.
There is described a method of operating a distribution system. The distribution system comprises a number of carriers wherein the carriers are adapted to carry one or more goods. A transport plane of the distribution system supports the carriers. A control device controls the drive means. During an initialization of the distribution system the control device pre-defines a pattern of safe points on the transport plane, wherein on the safe points a carrier can be placed. After the initialization of the distribution system the control device calculates partial routes for the carriers so that the end position of each partial route is either one of the safe points or has a free path to one of the safe points to be reachable in the next partial route.
G06Q 10/08 - Logistics, e.g. warehousing, loading or distribution; Inventory or stock management
B65G 1/00 - Storing articles, individually or in orderly arrangement, in warehouses or magazines
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor
G01N 35/04 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations - Details of the conveyor system
98.
METHOD FOR DETECTING AN ANALYTE WITH THE HELP OF METAL NANOPARTICLES ON AN ELECTRODE
The present invention relates to a method for detecting at least one analyte by electrochemical detection, a working electrode of an analyte sensor and an analyte sensor for detecting at least one analyte in a sample by electrochemical detection. The method of the present invention comprises the following steps: contacting a fluid sample suspected to comprise the at least one analyte with the surface of an electrode comprising at least one binding agent capable of binding to the analyte; contacting the fluid sample suspected to comprise the at least one analyte with at least one detection agent, wherein the at least one detection agent comprises at least a further binding agent capable of binding to the analyte and a label, wherein the label comprises a metal nanoparticle with a standard redox potential E° between 0 V and 1.2 V forming a detection complex on the surface of the electrode comprising at least the at least one binding agent, the at least one detection agent and the analyte; precipitating at least a part of the label onto the electrode surface; and the at least one detecting the at least one analyte by electrochemical detection.
The present invention relates to an antibody or an antigen binding fragment thereof that specifically binds to α- 1,6-core-fucosylated prostate specific antigen (PSA) and partial sequences thereof comprising the α-1,6-core-fucose residue. The antibodies and antigen binding fragments significantly discriminate between core-fucosylated PSA or core- fucosylated PSA partial sequences and other glycosylated PSA species and partial sequences thereof lacking the core-fucose residue, including aglycosylated PSA, as well as core- fucosylated glycan in other contexts. The present invention further relates to nucleic acid molecules encoding the light chain variable region or the heavy chain variable region of the antibody of the invention, as well as vectors comprising said nucleic acid molecules. The invention also relates to a host cell comprising the vector(s) of the invention, as well as to methods for the production of an antibody or antigen binding fragment of the invention comprising culturing the host cell of the invention under suitable conditions and isolating the antibody produced. Furthermore, the present invention relates to an antibody obtainable by the method of the invention, to a composition comprising at least one of the antibody or antigen binding fragment of the invention, the nucleic acid molecule of the invention, the vector of the invention, the host cell of the invention or the antibody produced by the method of the invention. The present invention also relates to the use of an antibody or antigen binding fragment of the invention for detecting and discriminating core-fucosylated PSA or core-fucosylated partial sequences thereof in biological samples.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
100.
COMPUTER-IMPLEMENTED METHOD FOR DETECTING AT LEAST ONE INTERFERENCE AND/OR AT LEAST ONE ARTEFACT IN AT LEAST ONE CHROMATOGRAM
A computer-implemented method for detecting at least one interference and/or at least one artefact in at least one chromatogram determined by at least one mass spectrometry device (110) is proposed. The chromatogram comprises a plurality of raw data points. The method comprises the following steps: a) retrieving the at least one chromatogram by at least one processing device (126); b) applying at least one peak fit modelling to the chromatogram by using the processing device (126); c) determining information about residuals of the raw data points by using the processing device (126); d) detecting the at least one interference and/or the at least one artefact by using the processing device (126) by comparing the determined information about the residuals with at least one pre-determined threshold, wherein, if the determined information about the residuals exceed the pre-determined threshold, the at least one interference and/or the at least one artefact is detected.
patents
